UK-based Sterling Pharma Solutions has formed as an independent contract development and manufacturing organisation (CDMO) following a management buyout (MBO) of the UK based Dudley site.
Formerly operating as Shasun Pharma Solutions within Strides Shasun, the process of divesting the business to the current management team was completed in September 2016.
Following the MBO, the newly divested business has been rebranded and launched as Sterling Pharma Solutions. The CDMO will specialise in delivering API development and manufacturing solutions to support global pharmaceutical companies across the entire product lifecycle.
The management team will be led by Kevin Cook as CEO. Kevin joined the Dudley site in 1993. He says: “We are delighted to complete the MBO and excited about building a global API services business with roots in the north east of England. Our offering is compelling as we can take projects from proof of concept to commercial scale manufacture all on one site. We also have the capabilities to handle the most hazardous chemical processes safely.
“We have experienced significant growth in the US and Europe in recent years and believe the extensive capabilities at our site, coupled with our heritage in the API services sector, provide us with an excellent foundation to become the leading partner and provider of API services to the pharmaceutical industry.”
Sterling Pharma Solutions’ site in Dudley, UK, has been in existence for 47 years and is the UK’s largest provider of API development and manufacturing services to the pharmaceutical industry.